202197-77-1

Usage

Uses

Used in Pharmaceutical Industry:
7-IODO-1H-QUINAZOLIN-4-ONE is used as a pharmaceutical compound for its antiviral and anticancer properties, offering potential therapeutic benefits in treating various diseases and conditions.
Used in Organic Synthesis:
7-IODO-1H-QUINAZOLIN-4-ONE is used as a precursor in organic synthesis, enabling the creation of other complex molecules for various applications, such as drug development and material science.
Used in Research and Development:
7-IODO-1H-QUINAZOLIN-4-ONE is used as a research tool in the study of organic reactions and drug discovery, contributing to the advancement of scientific knowledge and the development of new pharmaceuticals and materials.

Upstream product

• 20776-54-9 2-amino-4-iodobenzoic acid 
• 77287-34-4 formamide 
• 90004-09-4 7-aminoquinazolin-4-one 
• 116529-62-5 4-iodo-2-nitro benzoic acid 
• 41252-97-5 4-iodo-2-nitrotoluene 

Downstream Products

• 202197-78-2 4-chloro-7-iodoquinazoline 

Relevant academic research and scientific papers

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

CANCER TREATMENT METHOD

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

Anilinoquinazolines as protein tyrosine kinase inhibitors

Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

Anilinoquinazaolines as protein tyrosine kianse inhibitors

Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

Cancer treatment method

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.